Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

Based on 537 first isolates · SURG · Skin / wound infection · 2025-09-28 → 2026-09-27
Surgery
Per-organism detail: SURG wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 53 % (49 %–58 %)
Best two-drug combination: vancomycin + meropenem covers 99 % (97 %–99 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (16 %), Escherichia coli (12 %), Proteus mirabilis (9 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
53 %
62 %
n = 47
meropenem MEM
trend · Pseudomonas aeruginosa reserve
45 %
36 %
n = 47
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
42 %
30 %
n = 47
42 %
36 %
n = 47
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
40 %
47 %
n = 47
ceftriaxone CRO
trend · Escherichia coli
29 %
23 %
n = 47
26 %
21 %
n = 47
25 %
30 %
n = 47
15 %
13 %
n = 47
mecillinam MEC
not for this site
0 %
0 %
n = 47
trimethoprim TMP
not for this site
0 %
0 %
n = 47
nitrofurantoin NIT
not for this site
0 %
0 %
n = 47

Most likely organisms for this profile

Staphylococcus aureus
42 %
Pseudomonas aeruginosa
16 %
Enterococcus faecalis
12 %
Escherichia coli
12 %
Proteus mirabilis
9 %
Citrobacter freundii
5 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.